Roth Capital Remains Positive on Actinium Pharma (ATNM) as Iomab-B Gains Orphan Designation in Europe
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Roth Capital affirms Actinium Pharmaceuticals (NYSE: ATNM) with a Buy rating and $5 price target after the company announced that the Company’s lead asset, Iomab-B, has been granted orphan designation in the European Union (EU) by the European Medicines Agency (EMA). Iomab-B is intended to be used, upon approval, in preparing patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are over the age of 55 for a bone marrow transplant (BMT).
Roth commented today,
With U.S. and E.U. orphan designation in hand we believe that there will be greater regulatory interactions and attention given that will help guide Iomab-B studies and keep them on track. The lead focus for the company is Iomab-B in its ongoing Phase III SIERRA study in BMT conditioning, which should read out in 2H18. Enrollment of 150 patients is expected to be completed by the end of 2017. The amount of time required for the treatment compared to current conditioning regimens as well as the overall cost should be significantly reduced, if approved. Additionally, the SME status granted by the E.U. is somewhat analogous to Breakthrough Therapy designation and allows for enhanced regulatory support as well.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roth Capital Affirms Bioblast Pharma (ORPN) at 'Buy'; Sees Trehalose PK Data as 'Meaningful'
- BMO Capital Raises Price Target on ManpowerGroup (MAN) Following 3Q Surprise
- Jefferies Raises Price Target on FMC Technologies (FTI) After Adjusting Estimates
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!